Stay up-to-date with the latest Sciety news

Discover the latest updates on our company and investments in life science

Sciety news

EMPE Diagnostics raises MSEK 9 for launch in India


This week, EMPE Diagnostics completed a new share issue of a total of SEK 9.2 million with Sciety. The company has developed a quick test for tuberculosis and the new capital will support the establishment of operations in India where tuberculosis is a major health problem. “With the new capital,…

Read more

The Sciety syndicate invests MSEK 15 in cutting-edge company specializing in DNA sequencing


This week, Single Technologies completed a new share issue of 15 million SEK with Sciety. The company has developed a DNA sequencing solution, which makes it possible to analyse larger amounts of data faster and cheaper than before. The new capital will be used to adapt the instrument for NGS…

Read more

Athera Biotechnologies raises MSEK 55 with the help of Sciety


This week, pharmaceutical company Athera Biotechnologies, completed a new share issue of SEK 55 million in which Industrifonden, Östersjöstiftelsen and the Sciety investment syndicate participated. The new capital is to be used for a clinical Phase 2 study and the company aims at being acquired by a major player after…

Read more

Sciety raises new capital for a medtech company to continue their expansion in Europe


Medtech company Likvor raises new capital for its continued expansion in Europe. They currently have about ten hospitals as clients. The company’s system is used to diagnose the dementia-like disorder, NPH. Likvor has developed a system for the monitoring of cerebrospinal spinal fluid dynamics to investigate and follow up the…

Read more

Sciety raises new capital for pharma company within fat-related diseases


Lipigon Pharmaceuticals has raised SEK 8 million in a new share issue to finance the continued pre-clinical development of pharmaceuticals within fat-related diseases, so-called lipid-related disorders. Lipid imbalance cause common diseases, such as diabetes and cardiovascular diseases, but also a number of rare diseases currently lacking sufficient treatment. Based on…

Read more

Sciety arranges two private placements


Sciety is currently capitalizing a Phase II pharmaceutical company and a DNA sequencing tech company––both via private placements. The companies operate in high growth markets and raise new capital to achieve product development goals that will lead to acquisition within the next twenty-four months.     Drug candidate with a…

Read more

New venture at Sciety – develops drugs for diseases caused by high levels of blood lipids


Lipid imbalances does not only cause common diseases such as diabetes and cardiovascular diseases but also various rare diseases. The pharma company Lipigon is specialised in diseases caused by lipid imbalances, with an initial focus on rare diseases that lack adequate treatments.   New candidate for treatment of severe disease…

Read more

Sciety raises new capital to medtech company in neurology and cancer


CARTANA raised almost 10 million SEK in a share issue that was fully subscribed at the end of September. The company has developed reagents for analysing tissue samples in drug development processes and is based at Karolinska in Stockholm. The new capital will be used for the sale of CARTANA’s…

Read more

New venture at Sciety – wants to help researchers in the search for new treatments


Cartana is based at Karolinska Institute in Stockholm and has developed a new technology for researchers to analyse tissue samples in drug development processes. The company is ready to launch at the market for brain research and will launch on the market for cancer research within a few years.  …

Read more

5 common questions about investing in unlisted companies


Last updated: 2023-09-12 If you’re used to buying shares on the stock market, it doesn’t have to be a big leap to invest in unlisted companies as well. At Sciety, we frequently receive questions from people who are considering making their first investment in an unlisted company. Practically speaking, how…

Read more